Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Coherus BioSciences (CHRS) stocks in Canada
Learn how to easily invest in Coherus BioSciences stocks.
Coherus BioSciences is a biotechnology business based in the US. Coherus BioSciences stocks (CHRS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.42 – a decrease of 5.25% over the previous week. Coherus BioSciences employs 334 staff and has a trailing 12-month revenue of around $363.6 million.
How to buy shares in Coherus BioSciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CHRS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Coherus BioSciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Coherus BioSciences?
- Has coronavirus impacted Coherus BioSciences shares?
- Coherus BioSciences shares summary
- Compare share dealing platforms
- Is Coherus BioSciences stock a buy or sell?
- Coherus BioSciences performance over time
- Coherus BioSciences's financials
- How volatile are Coherus BioSciences shares?
- Does Coherus BioSciences pay a dividend?
- Other common questions
How has Coronavirus impacted Coherus BioSciences's stock price?
Since the stock market crash in March caused by coronavirus, Coherus BioSciences's stock price has had significant negative movement.
Its last market close was $13.9, which is 38.30% down on its pre-crash value of $22.53 and 27.97% up on the lowest point reached during the March crash when the stocks fell as low as $10.8616.
If you had bought $1,000 worth of Coherus BioSciences stocks at the start of February 2020, those stocks would have been worth $760.17 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $742.54.
Coherus BioSciences stock price (NASDAQ:CHRS)Use our graph to track the performance of CHRS stocks over time.
Coherus BioSciences shares at a glance
|Latest market close||$13.90|
|52-week range||$12.21 - $22.22|
|50-day moving average||$17.50|
|200-day moving average||$15.42|
|Wall St. target price||$25.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.12|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Coherus BioSciences price performance over time
|1 week (2022-01-06)||-7.89%|
|1 month (2021-12-15)||-19.14%|
|3 months (2021-10-15)||-18.24%|
|6 months (2021-07-16)||6.84%|
|1 year (2021-01-15)||-21.60%|
|2 years (2020-01-16)||-30.03%|
|3 years (2019-01-16)||20.76%|
|5 years (2017-01-13)||27.15|
Is Coherus BioSciences under- or over-valued?
Valuing Coherus BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Coherus BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Coherus BioSciences's EBITDA
Coherus BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $159.2 million.
The EBITDA is a measure of a Coherus BioSciences's overall financial performance and is widely used to measure a its profitability.
Coherus BioSciences financials
|Revenue TTM||$363.6 million|
|Gross profit TTM||$295.4 million|
|Return on assets TTM||-16.14%|
|Return on equity TTM||-119.88%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
Coherus BioSciences share dividends
We're not expecting Coherus BioSciences to pay a dividend over the next 12 months.
Coherus BioSciences share price volatility
Over the last 12 months, Coherus BioSciences's shares have ranged in value from as little as $12.21 up to $22.2166. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherus BioSciences's is 0.9159. This would suggest that Coherus BioSciences's shares are less volatile than average (for this exchange).
Coherus BioSciences overview
Coherus BioSciences, Inc. , a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.
Stocks similar to Coherus BioSciences
Frequently asked questions
Coherus BioSciences in the news
Coherus BioSciences : and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody - Form 8-K
COHERUS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
More guides on Finder
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
Pendle (PENDLE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
The ChampCoin (TCC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.
GreenTrust (GNT) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy GreenTrust, lists some exchanges where you can get it and provides daily price data on GNT.
Ask an Expert
You must be logged in to post a comment.